Dr Foote on the Ongoing Debate Over Upfront EGFR Inhibitor Use in CRC
Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.
Read More
Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC
Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.
Dr. Foote on the Quest to Determine Optimal Sequencing in Late-line mCRC
Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML
FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable/Metastatic MSI-H/dMMR CRC
Anna Parks Receives American Society of Hematology Junior Faculty Scholar Award
Building the Next Generation of Oncology PAs